Capital Fund Management S.A. Exact Sciences Corp Transaction History

Capital Fund Management S.A.

$37.9 Billion
Q4 2024

A detailed history of Capital Fund Management S.A. transactions in Exact Sciences Corp stock. As of the latest transaction made, Capital Fund Management S.A. holds 39,200 shares of EXAS stock, worth $1.93 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

39,200

Previous 85,600 54.21%

Holding current value

$1.93 Million

Previous $5.83 Million 62.22%

% of portfolio

0.01%

Previous 0.02%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$41.33 - $74.26 $2.67 Million - $4.79 Million	64,496 New	64,496 $2.72 Million
Q4 2019 Feb 13, 2020	SELL	$77.66 - $99.74 $2.78 Million - $3.56 Million	-35,737 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$90.37 - $122.49 $2.89 Million - $3.92 Million	-32,031 Reduced 47.27%	35,737 $3.23 Million
Q2 2019 Aug 12, 2019	BUY	$89.51 - $118.04 $2.12 Million - $2.79 Million	23,661 Added 53.64%	67,768 $8 Million
Q1 2019 May 13, 2019	BUY	$61.98 - $96.5 $2.31 Million - $3.6 Million	37,295 Added 547.49%	44,107 $3.82 Million
Q4 2018 Feb 13, 2019	SELL	$56.04 - $82.66 $2.29 Million - $3.38 Million	-40,900 Reduced 85.72%	6,812 $430,000
Q3 2018 Nov 14, 2018	SELL	$48.29 - $80.6 $587,689 - $980,901	-12,170 Reduced 20.32%	47,712 $3.77 Million
Q2 2018 Aug 14, 2018	SELL	$37.84 - $69.96 $7.24 Million - $13.4 Million	-191,251 Reduced 76.16%	59,882 $3.58 Million
Q1 2018 May 15, 2018	BUY	$39.82 - $57.53 $10 Million - $14.4 Million	251,133 New	251,133 $10.1 Million

Others Institutions Holding EXAS

# of Institutions

672

Shares Held

164M

Call Options Held

4.25M

Put Options Held

1.89M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $8.72B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Capital Fund Management S.A. with notifications on news.

Account

Capital Fund Management S.A. Exact Sciences Corp Transaction History